
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is a high potential company in the commercial-stage medical diagnostics technology sector, with its EsoGuard and EsoCheck having received positive support from medical associations. With progress being made in securing commercial payors, the company currently holds a BUY rating and a price target of $2.50, potentially offering significant growth opportunities. However, financial and regulatory challenges remain as potential risks for the company's future success.
Bears say
Lucid Diagnostics is in the early stages of commercialization which leads to relatively low revenue. The company is facing growth challenges and its financials showed a pro forma net loss of $10.5 million in Q1 with a projected increase in revenue in 2026/27. Although the company has potential for success in the billion-dollar market, the risks may outweigh the potential rewards at this point in time. Lucid has made progress with Medicare coverage but still has not negotiated a price for its services, and the company's inclusion in NCCN guidelines improves its chances of obtaining Medicare coverage, but there are no guarantees. The company's growth drivers include expanding into the LBM market, signing more commercial payers, and increasing collections and revenue from prior period claims, but these are not guaranteed and do not guarantee a positive outlook for the company.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares